At Next Generation PDT we fully embrace the approach that cancer is a systemic condition and requires a non-toxic therapeutic strategy that treats the patients entire body. The ability of NGPDT to specifically identify and destroy cancer cells while leaving the rest of the body's normal cells unharmed is a revolutionary advancement compared to earlier generations of Photo Dynamic Therapy (PDT) and is a viable option to the highly invasive and toxic therapies associated with chemotherapy, surgery and radiation.

We are constantly developing, testing, and researching our proprietary treatment agents and equipment to give our patients a state of the art, effective cancer treatment solution. Our end goal is to make the widespread fear of cancer against humanity a notion of the past.


As a PDT (Photo Dynamic Therapy) research and development company, our activities touch many peoples lives. Our international team of dedicated professionals, research scientists, biochemists and physicians, have researched and developed a uniquely effective 'Next Generation PDT'' photosensitizer agent sensitive to our specially designed full-body light treatment beds and laser light treatment systems. NGPDT is showing great prospect in the treatment of many forms of cancer, including solitary, metastatic and of advanced stage cancers. NGPDT's pioneering discoveries are set to change the face of medicine forever.

We strive to make sure our Next Generation PDT offers true value for money and positive outcomes for those being treated. We take pride in our contribution to medical science and are continuously working to improve and develop even more advanced PDT technologies.


Photo Dynamic Therapy is not a new concept, the therapeutic properties of light have been known for thousands of years. It was only in the last century however, that Photo Dynamic Therapy (PDT) was developed.

  • Neils Finsen won a Nobel Prize in 1903 for using light treatment to cure Lupus.
  • The first clinical application of Photo Dynamic Therapy (PDT) was described by Von Tappeiner and Jesionek in 1903.
  • In 1913 the German physician Friedrich Meyer–Betz performed the first study on humans with great success.
  • In 1975 Dougherty Et Al. reported that hematoporphyrin derivative (HpD) in combination with red light could completely eradicate mammary tumour growth in rats and mice.

Following these successful studies, numerous trials were initiated involving a variety of cancers and photosensitizers. This resulted in the approval of PDT for the treatment of bladder cancer in Canada in 1993. Then, in the USA, Thomas J. Dougherty PhD and Oncology Professor, expanded clinical trials eventually forming the International Photo Dynamic Association in 1986. Due to his work, in December 1995 the U.S. Food and Drug Administration (FDA) approved the first Photo-Sensitizing agent for use in Photo Dynamic Therapies.

It is from these beginnings that Next Generation PDT has evolved and will continue to evolve with improved treatment protocols, more advanced technologies and highly effective photosensitizing agents to facilitate the fight against cancer.

Interstitial PDT Cancer Treatment in ProgressNext Generation PDT Full Body TreatmentNext Generation PDT Treatment LightsNext Generation Equipment and Diagnosis TechnologyFirst Class Cancer Treatment Centre Facilities